Claims for Patent: 11,291,665

Summary for Patent: 11,291,665

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Tabuteau; Herriot (New York, NY)
Assignee:	ANTECIP BIOVENTURES II LLC (New York, NY)
Application Number:	17/207,256
Patent Claims:	1. A method of increasing dextromethorphan plasma levels, comprising co-administering bupropion and dextromethorphan once a day or twice a day for at least 8 consecutive days to a human being who is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan; wherein about 100 mg to about 220 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion is co-administered with about 40 mg to about 70 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan, once or twice a day; and wherein the bupropion and the dextromethorphan are the only therapeutically active agents to be co-administered and co-administering the bupropion and the dextromethorphan results in an AUC.sub.0-inf of dextromethorphan on the eighth day that is at least about 20 times the AUC.sub.0-inf of dextromethorphan that would result from administering the same daily dose of the dextromethorphan without the bupropion for eight consecutive days. 2. The method of claim 1, wherein co-administering the bupropion and the dextromethorphan results in an AUC.sub.0-inf of dextromethorphan on the eighth day that is about 20 times to about 175 times the AUC.sub.0-inf of dextromethorphan that would result from administering the same daily dose of the dextromethorphan without the bupropion for eight consecutive days. 3. The method of claim 2, wherein about 100 mg to about 150 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion, is co-administered with about 40 mg to about 70 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan, once a day or twice a day. 4. The method of claim 3, wherein the AUC.sub.0-inf of dextromethorphan on the eighth day is about 3,700 nghr/mL. 5. The method of claim 3, wherein the AUC.sub.0-inf of dextromethorphan on the eighth day is about 2,400 nghr/mL to 7,327 nghr/mL. 6. The method of claim 5, wherein about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion, is co-administered with about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan, once a day or twice a day. 7. The method of claim 5, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of depression. 8. The method of claim 5, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of nicotine addiction. 9. The method of claim 5, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of agitation associated with Alzheimer's disease. 10. The method of claim 5, wherein the C.sub.max of dextromethorphan on the eighth day is about 69 ng/mL to about 154 ng/mL. 11. The method of claim 10, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of depression. 12. The method of claim 10, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of nicotine addiction. 13. The method of claim 10, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of agitation associated with Alzheimer's disease. 14. The method of claim 10, wherein AUC.sub.0-12 of bupropion on the eighth day is at least 600 nghr/mL. 15. The method of claim 14, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of depression. 16. The method of claim 14, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of nicotine addiction. 17. The method of claim 14, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of agitation associated with Alzheimer's disease. 18. The method of claim 14, wherein the bupropion and dextromethorphan are co-administered once a day or twice a day for at least 14 consecutive days. 19. The method of claim 14, wherein the bupropion and dextromethorphan are co-administered once a day or twice a day for at least 30 consecutive days. 20. The method of claim 14, wherein the human being is converted to poor metabolizer status on the eighth day after co-administering the bupropion and the dextromethorphan.